Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 33,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 2 Interventional Results available

Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease

NCT00667004
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ecabet ophthalmic solution, placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
View directory record Official record
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants

NCT03476447
View directory record Official record
Conditions
Gut Microbiome
Interventions
B. infantis EVC001, Lactose
Other
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
2 Months to 4 Months
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trigger Point Dry Needling With and Without Electrical Stimulation in Healthy Subjects

NCT07384247
View directory record Official record
Conditions
People With Identified Painful Trigger Points (Tp) Within the Soleus and Gastrocnemius Muscles Complex, Healthy Subjects or Volunteers
Interventions
Dry needling with electrical stimulation, Dry needling, Electrical stimulation, Sham
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OEA for Targeting Lipid Metabolism in GWI

NCT05252949
View directory record Official record
Conditions
Gulf War Illness
Interventions
Oleoylethanolamide (OEA), Placebo
Dietary Supplement
Lead sponsor
Roskamp Institute Inc.
Other
Eligibility
Up to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

NCT04366349
View directory record Official record
Conditions
Healthy Volunteers, Asthma
Interventions
melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg), Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 20, 2026, 3:18 AM EDT
Not listed Not applicable Interventional

Dietary Supplementation on Fat Oxidation

NCT06548048
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
Dietary Supplement
Lead sponsor
Brightseed
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Not applicable Interventional Results available

Nicotine and Behavior in Adult ADHD

NCT00573248
View directory record Official record
Conditions
ADHD
Interventions
Nicotine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Oct 20, 2026, 3:18 AM EDT
Not listed Not applicable Interventional

E-STIM Trial: Comparing the Efficacy of the Empi Select TENS to a Control for the Treatment of Chronic Lower Back Pain

NCT00709748
View directory record Official record
Conditions
Lower Back Pain
Interventions
Empi Select TENS Device, Placebo
Device
Lead sponsor
Empi, A DJO Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Fair Oaks, California • Pensacola, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

NCT04041648
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 20, 2026, 3:18 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

NCT04300855
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Sunphenon, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Varenicline on Cigarette Self Administration

NCT00731055
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 20, 2026, 3:18 AM EDT
Recruiting Phase 2 Interventional

The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence

NCT05814055
View directory record Official record
Conditions
Smoking
Interventions
Placebo, AB-free kava
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 3:18 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT05938699
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
NCX 470, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 20, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

NCT03252093
View directory record Official record
Conditions
Coronary Artery Bypass Surgery, Cognitive Impairment
Interventions
Angiotensin-(1-7), Placebo for Angiotensin-(1-7)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
60 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Tucson, Arizona • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 20, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

NCT00784693
View directory record Official record
Conditions
Endometriosis
Interventions
Tanezumab, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Results available

Propranolol for Sleep Apnea Therapy

NCT03049306
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Propranolol Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 20, 2026, 3:18 AM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Major Depression

NCT00420004
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, Escitalopram
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 2Phase 3 Interventional

Aripiprazole and Topiramate on Free-Choice Alcohol Use

NCT00884884
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Double Placebo, Aripiprazole 15, placebo, Aripiprazole 7.5, Placebo, Topiramate 100, Placebo, Topiramate 200, Placebo, Topiramate 100, Aripiprazole 15, Topiramate 100, Aripiprazole 7.5, Topiramate 100, Aripiprazole 15mg, Topiramate 200, Aripiprazole 7.5mg, Topiramate 200, Aripiprazole 15
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 20, 2026, 3:18 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 20, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 20, 2026, 3:18 AM EDT